AAAAAA

   
Results: 1-8 |
Results: 8
IMPACT OF DONOR LYMPHOCYTE INFUSION FOR HEMATOLOGICAL MALIGNANCY RELAPSED AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: ZEDER K WALLER EK REDEI I CONNAGHAN DG FLEMING WH GELLER RB HEFFNER LT HILLYER CD HOLDEN J HOLLAND K JONES W MCCOLLUM J MOGUL M PHILLIPS C RODEY G WINGARD JR WINTON E YEAGER AM DEVINE S
Citation: K. Zeder et al., IMPACT OF DONOR LYMPHOCYTE INFUSION FOR HEMATOLOGICAL MALIGNANCY RELAPSED AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION, Cancer research, therapy & control, 5(4), 1998, pp. 221-228
DAILY BUSULFAN PLUS MELPHALAN AND AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR HIGH-RISK SOLID TUMORS - PHARMACOKINETIC STUDIES AND CLINICAL-RESULTS
Authors: YEAGER AM OSOWSKI C MULLINS R KAPLAN C BOYER M DEVINE S FORTE K LAUER M MOGUL M OLSON E OLSON T TURNER C VEGA R
Citation: Am. Yeager et al., DAILY BUSULFAN PLUS MELPHALAN AND AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR HIGH-RISK SOLID TUMORS - PHARMACOKINETIC STUDIES AND CLINICAL-RESULTS, Experimental hematology, 25(8), 1997, pp. 301-301
TANDEM PERIPHERAL-BLOOD PROGENITOR-CELL (PBPC) TRANSPLANT IN CHILDRENWITH HIGH-RISK NEUROBLASTOMA AND SARCOMAS
Authors: GRUPP SA MOGUL M ADAMS R WEINSTEIN HJ DILLER L
Citation: Sa. Grupp et al., TANDEM PERIPHERAL-BLOOD PROGENITOR-CELL (PBPC) TRANSPLANT IN CHILDRENWITH HIGH-RISK NEUROBLASTOMA AND SARCOMAS, Blood, 90(10), 1997, pp. 1036-1036
THE IMPACT OF DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH RELAPSED HEMATOLOGICAL MALIGNANCY
Authors: ZEDER K WELLER E PHILLIPS C FLEMING H YAEGER A HOLLAND K MOGUL M MCCOLLUM J DEVINE S
Citation: K. Zeder et al., THE IMPACT OF DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH RELAPSED HEMATOLOGICAL MALIGNANCY, Blood, 88(10), 1996, pp. 3817-3817
HYDROXYCHLOROQUINE FOR THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE
Authors: GILMAN A MORRIS C MOGUL M MAZUMDER A LEE CK GINGRICH R GOLDMAN F TRIGG M
Citation: A. Gilman et al., HYDROXYCHLOROQUINE FOR THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE, Blood, 88(10), 1996, pp. 2421-2421
MDR1 P-GLYCOPROTEIN EXPRESSION AND FUNCTION DURING HUMAN HEMATOLYMPHOPOIETIC DIFFERENTIATION AND MYELOGENOUS LEUKEMIA
Authors: ARCICI RJ VISSER M DUNISSIECONOMOU K MOGUL M DAHL G
Citation: Rj. Arcici et al., MDR1 P-GLYCOPROTEIN EXPRESSION AND FUNCTION DURING HUMAN HEMATOLYMPHOPOIETIC DIFFERENTIATION AND MYELOGENOUS LEUKEMIA, Experimental hematology, 21(8), 1993, pp. 1078-1078
LANGERHANS CELL HISTIOCYTOSIS PRESENTING WITH THE SUPERIOR VENA-CAVA SYNDROME - A CASE-REPORT
Authors: MOGUL M HARTMAN G DONALDSON S GELB A LINK M AMYLON M GLADER B
Citation: M. Mogul et al., LANGERHANS CELL HISTIOCYTOSIS PRESENTING WITH THE SUPERIOR VENA-CAVA SYNDROME - A CASE-REPORT, Medical and pediatric oncology, 21(6), 1993, pp. 456-459
A PEDIATRIC-ONCOLOGY-GROUP (POG) PHASE-II TRIAL OF MITOXANTRONE, ETOPOSIDE AND CYCLOSPORINE A (MEC) THERAPY FOR RELAPSED AND REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML)
Authors: DAHL G DUNUSSI K MOGUL M BROPHY N LOWE K GRIER H SIKIC B WEINSTEIN H ARCECI R
Citation: G. Dahl et al., A PEDIATRIC-ONCOLOGY-GROUP (POG) PHASE-II TRIAL OF MITOXANTRONE, ETOPOSIDE AND CYCLOSPORINE A (MEC) THERAPY FOR RELAPSED AND REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML), Blood, 82(10), 1993, pp. 10000195-10000195
Risultati: 1-8 |